<DOC>
	<DOC>NCT01183169</DOC>
	<brief_summary>The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy alisporivir (ALV; DEB025) with PEG and RBV versus placebo with PEG and RBV.</brief_summary>
	<brief_title>Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Inclusion criteria: Chronic HCV genotype 1 viral infection HCV RNA â‰¥ 1,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening Previous nonresponders/relapsers to PEG and RBV after treatment for at least 12 weeks Exclusion criteria: Treatment with any antiHCV drug (whether approved or investigational) within 3 months prior to screening Women of childbearing potential unless using highly effective Any other cause of relevant liver disease other than HCV Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>